悦康药业子公司YKYY018雾化吸入剂获临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd. (referred to as "Yuyuan Ketech"), has received approval from the National Medical Products Administration (NMPA) for two clinical trial approval notices regarding the YKYY018 aerosol inhalation agent for post-exposure prophylaxis in patients exposed to respiratory syncytial virus (RSV) and for the treatment of RSV infection [1] Group 1 - The company has obtained NMPA approval for YKYY018 to be used in clinical trials [1] - The clinical trials will include Phase I studies for the aerosol inhalation agent [1]